Form 4: AYTU Director Carl Dockery Granted 10,000 Restricted Shares

AYTU BioPharma, Inc. Director Carl Dockery was granted 10,000 shares of restricted common stock, vesting on October 3, 2026.

Summary

• Carl Dockery, a Director of AYTU BioPharma, Inc., was granted 10,000 shares of common stock.
• The transaction occurred on October 3, 2025, with a price of $0 per share, indicating a grant of restricted stock.
• These restricted shares will vest on October 3, 2026.
• Following this transaction, Carl Dockery beneficially owns 20,440 shares of AYTU common stock.
• A Limited Power of Attorney, dated September 17, 2025, authorizes specific individuals to execute and file Section 16(a) reports on behalf of Carl Dockery.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is generally a positive signal, indicating alignment of interests and a commitment to long-term value creation. It's a standard compensation practice, not indicative of immediate operational or financial distress, but also not a major catalyst for significant positive change.

Positives

• Grant of restricted stock aligns director's interests with long-term shareholder value.
• Increases director's direct ownership in the company, demonstrating commitment.

Negatives

• No immediate cash inflow for the director from this grant until vesting.
• The value of the grant is dependent on the future stock price of AYTU.

Risks

• The value of the restricted stock grant is subject to the future performance and market price of AYTU BioPharma, Inc. common stock.
• The shares are subject to a vesting period until October 3, 2026, meaning the director does not have full ownership until that date.

Future Outlook

The grant of restricted stock with a future vesting date indicates a long-term incentive for the director, aligning their interests with the company's future performance through October 2026.

Management Comments

• The filing includes a Limited Power of Attorney signed by Carl Dockery, authorizing specific individuals to execute and file Section 16(a) reports on his behalf, indicating a standard corporate governance practice for directors.

Industry Context

Equity grants to directors and executives are a common practice in the biopharmaceutical industry, used to attract and retain talent, and to align management and board interests with long-term shareholder value. Such grants are often time-vested to encourage sustained commitment.

Comparison to Industry Standards

• The grant of restricted stock to a director at a $0 price, vesting over a period, is a standard form of equity compensation in publicly traded companies, particularly within the biopharma sector.
• This practice is consistent with compensation strategies observed across comparable companies aiming to incentivize long-term performance and retention.
• Specific comparable companies or projects are not mentioned in the filing, but this type of grant is a widely accepted benchmark for director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with long-term shareholder value due to equity ownership.
• Management/Board: Standard compensation practice for directors, reinforcing commitment and retention.

Next Steps

• The 10,000 restricted shares granted to Carl Dockery will vest on October 3, 2026.
• Carl Dockery will continue to be subject to Section 16(a) reporting requirements for his holdings in AYTU BioPharma, Inc.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock to a director as part of their compensation package. While it signifies alignment of interests, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard governance and compensation event.

Keywords

AYTU BioPharma, AYTU, Carl Dockery, Restricted Stock Grant, Form 4, Insider Ownership, Director Compensation, Equity Compensation, Biopharma